At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 96 enrolled
Drug / intervention
Florbetapir (18F)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate the Improvement in Reader Accuracy When Using a Read Method That Incorporates Commercially Available Quantitative Analysis Software as an Adjunct to the Clinical Visual Interpretation of Amyvid Brain Scans
In Brief
A Phase 4 clinical trial evaluating Florbetapir (18F) for Alzheimer's Disease. Completed, enrolled 96 participants across 1 site.
Detailed Summary
This study will evaluate whether the addition of quantitation as an adjunct to visual interpretations significantly improves the accuracy of Amyvid scan interpretation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesNetherlands
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMar 2014
First PostedApr 2014
Primary CompletionMay 2014
TodayJul 2026
First PostedApr 8, 2014
Enrollment StartMar 1, 2014
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 12.2 years ago
Interventions
Florbetapir (18F)drug
No Florbetapir (18F) will be administered in this study.